Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.

Breyanzi (lisocabtagene maraleucel) - BMS

Kymriah (tisagenlecleucel-T) - Novartis

Yescarta (axicabtagene ciloleucel) - Gilead

http://www.ncbi.nlm.nih.gov/pubmed/42716341

Ashley Schmitt; David Porter; Jenny Ahlstrom; Laura Zitella; Loretta Nastoupil; Mazyar Shadman; Meghan Gutierrez; Tara Graff

Sep 10, 2026